Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung.
Studies have indicated that although abundant levels of transgene expression could be achieved in the lungs of mice instilled with cationic lipid:pDNA complexes, the efficiency of gene transfer is low. As a consequence, a relatively large amount of the complex will need to be administered to the human lungs to achieve therapeutic efficacy for indications such as cystic fibrosis. Because all cationic lipids exhibit some level of cytotoxicity in vitro, we assessed the safety profile of one such cationic lipid, GL-67, following administration into the lungs of BALB/c mice. Dose-dependent pulmonary inflammation was observed that was characterized by infiltrates of neutrophils, and, to a lesser extent, macrophages and lymphocytes. The lesions in the lung were multifocal in nature and were manifested primarily at the junction of the terminal bronchioles and alveolar ducts. The degree of inflammation abated with time and there were no apparent permanent fibrotic lesions, even in animals that were treated at the highest doses. Analysis of the individual components of the complex revealed that the pulmonary inflammation was primarily cationic lipid-mediated with a minor contribution from the neutral co-lipid DOPE. Associated with the lesions in the lungs were elevated levels of the pro-inflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) that peaked at days 1-2 post-instillation but resolved to normal limits by day 14. Total cell counts, primarily of neutrophils, were also significantly elevated in the bronchoalveolar lavage fluids of GL-67:pDNA-treated mice between days 1 and 3 but returned to normal limits by day 14. No specific immune responses were detected against the cationic lipid or plasmid DNA in mice that had been either instilled or immunized with the individual components or complex, nor was there any evidence of complement activation. These studies indicate that a significant improvement in the potency of cationic lipid:pDNA formulations is desirable to minimize the toxicity associated with cationic lipids.
Scheule
R K
RK
Genzyme Corporation, Framingham, MA 01701-9322, USA.
St George
J A
JA
Bagley
R G
RG
Marshall
J
J
Kaplan
J M
JM
Akita
G Y
GY
Wang
K X
KX
Lee
E R
ER
Harris
D J
DJ
Jiang
C
C
Yew
N S
NS
Smith
A E
AE
Cheng
S H
SH
D000281:Administration, Intranasal; D000818:Animals; D000917:Antibody Formation; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002412:Cations / Q000276:immunology / Q000493:pharmacokinetics* / Q000633:toxicity; D003167:Complement Activation; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D016207:Cytokines / Q000032:analysis; D004247:DNA / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D018014:Gene Transfer Techniques / Q000009:adverse effects*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008055:Lipids / Q000276:immunology / Q000493:pharmacokinetics* / Q000633:toxicity; D008168:Lung / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D010714:Phosphatidylethanolamines; D010957:Plasmids / Q000235:genetics; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D019076:Transgenes
C505032:CFTR protein, human; D002412:Cations; D016207:Cytokines; D008055:Lipids; D010714:Phosphatidylethanolamines; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C020888:1,2-dielaidoylphosphatidylethanolamine; D004247:DNA